Lambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome in which the immune system attacks the connection ...

This pharma stock has made strong gains over the past 12 months thanks to its strong earnings. Now it is testing a fresh buy point.

("DyDo") has launched FIRDAPSE ® (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome ("LEMS").

Approximately 300 new patient evaluations for multiple sclerosis are performed annually. In addition, patients with myasthenia gravis, the Lambert-Eaton myasthenic syndrome, Guillain-Barre syndrome, ...

Firdapse, a treatment for Lambert-Eaton myasthenic syndrome, has provided the majority of Catalyst's revenue in recent quarters. Write to Josh Beckerman at josh.beckerman@wsj.com About Dow Jones ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

The medication is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that causes muscle weakness and fatigue. FIRDAPSE® is currently the only U.S ...